Motus GI said today that it named Timothy Moran as its new chief executive officer, effective October 1, replacing former CEO Mark Pomeranz who will assume the role of president and COO.
Moran has previously served ConvaTec‘s (LON:CTEC) Americas president and helped lead the company through its initial public offering in 2016. Prior to ConvaTec, Moran spent 18 years with Covidien and joined Medtronic (NYSE:MDT) after it’s acquisition, taking on the role of patient care and safety division GM and VP.
“I am thrilled to welcome Tim, an industry leader with significant experience in the commercialization of medical devices for hospitals, to the Motus GI team. We have made great progress over the last year in positioning Motus GI for the next stage of commercial growth. Recognizing the scope of our market opportunity, it was clear to me that bringing in a leader with the right commercial scale-up expertise would have a positive impact on Motus GI’s ability to maximize our potential. In Tim Moran, we have secured a highly talented commercial leader who will enable me to focus on continuing to strengthen our operations, clinical execution and innovation pipeline. We believe Tim’s leadership style, business acumen, and commercial track-record from ConvaTec, Medtronic and Covidien made him the best candidate to lead the company. I really look forward to working alongside Tim and the rest of our management team to pursue our vision of establishing Pure-Vu as the new standard of care for in-hospital colonoscopy,” Pomeranz said in a press release.
“Motus GI has a very compelling new medical product opportunity. The Pure-Vu System has the potential to improve the colonoscopy process, particularly in the inpatient setting where it may improve and accelerate patient care while potentially saving hospitals thousands of dollars per episode of care. I am excited and honored to assume the role of chief executive officer alongside Mark and the team who have made great strides in establishing the foundation for future growth. I believe my experience in sales, marketing and general management of critical care product portfolios will help drive Motus GI forward and build a strong commercial organization focused on the successful launch of the Pure-Vu System. I look forward to working closely with the board of directors, Mark and the rest of the team to advance our efforts in establishing Motus GI as a preeminent medical technology company,” Moran said in a prepared release.
“The combination of Tim’s commercial leadership expertise with Mark’s operational track record give Motus GI a powerful leadership team that we are confident can position our company to take advantage of the commercial opportunity in front of us. Along with the recent appointment of Jeff Hutchison as our VP of U.S. sales and commercial Operations, Tim solidifies a dynamic leadership team with the skills and experience that we believe is capable to build and grow a market-leading medical technology company,” board chair David Hochman said in a press release.
MedX Health said yesterday it named current president Scott Spearn as its new chief executive officer, with former CEO Rob von der Porten taking on the role of board chair from a retiring Gary Van Nest.
Spearn has held senior executive roles at multinational medical device companies and has spent 30 years in the industry, Ontario-based MedX Health said.
“With the recent launch of our DermSecure telemedicine platform and anticipating a global roll-out of this leading product, the transition of Scott’s role to CEO represents a natural evolution at MedX. Scott’s experience in building sales organizations and developing international markets in the medical device field will help accelerate our growth from our SIAscopy technology and our therapeutic and dental laser products,” von der Porten said in a press release.
“On behalf of the board, we want to thank Rob von der Porten for his leadership during challenging times over the past few years and developing with the MedX team solid product roadmaps such as the delivery of DermSecure,” Van Nest said in a prepared release.
“I am excited to be taking on the CEO role, leading a dedicated team of hard-working people. MedX is a great Canadian company with innovative products and robust technology that is making a big difference in the health of people’s lives around the world,” Spearn said in prepared remarks.
NorthStar Medical Technologies said earlier this month it appointed prez and COO Stephen Merrick as its president and CEO, replacing outgoing chair and CEO George Messina, who has been named chairman emeritus and president and CEO of wholly-owned subsidiary NorthStar Nuclear Therapies.
Prior to joining NorthStar, Merrick served as Baxter (NYSE:BAX) International’s hospital product biz international marketing VP, and also held positions with Mallinckrodt Pharma, Bristol-Myers Squibb and Eli Lilly.
NorthStar said that Hendricks Holding Co chair Diane Hendricks assumed the chairperson role for both companies.
“As founder, George has been the driving force from NorthStar’s inception through FDA approval of the RadioGenixSystem to the initial commercial sale of domestically produced Mo-99. We thank George for his successful leadership in NorthStar’s effort to become the first US-based producer of Mo-99. George’s passion and dedication were critical to building NorthStar into a global leader in the development of novel technologies for the production of medical isotopes for medical imaging. We are excited that George is assuming the leadership of NNT as president and chief executive officer. Targeted alpha therapy isotopes, including Actinium-225, produced by NNT have been identified as potential options in the treatment of certain cancers and infectious diseases. NNT’s therapeutic isotopes will offer more patients the potential for improved outcomes that were previously constrained by inadequate TAT isotope supply. We are looking to George to achieve similar success leading NNT as he has done with NorthStar,” Hendricks said in a prepared statement. “NorthStar is at a transformative point in its evolution from a development stage company to being the first domestic supplier of Mo-99, and we are excited that Steve has agreed to become NorthStar’s president and cEO. This company is strongly positioned for rapid growth in the US market, and there are attractive opportunities for NorthStar to grow outside the United States as well. Steve’s broad executive experience in the pharmaceutical industry at Bristol-Myers Squibb, Mallinckrodt and Baxter Healthcare, as well as his expertise in product development and driving domestic and global market demand are invaluable to NorthStar’s future success. The board of managers believes that this organizational realignment allows NorthStar to capitalize on both George and Steve’s strengths.”
The Wellesley, Mass.-based company said that Hershberger has spent more than 25 years in global finance management, and has held finance VP, controller and chief accounting officer positions with NxStage Medical (NSDQ:NXTM).
“In addition to his broad financial acumen and decades-long career in manufacturing and life sciences companies, Kevin has an excellent reputation for building strong teams and structuring successful companies. At Lumicell, we know that great companies start with great technology – but great technology doesn’t come to fruition without great people implementing a strong strategy. Kevin will join our leadership team and help pave the way for the future success of our organization,” CEO Kelly Londy said in a press release.
“It’s an exciting time to be joining the team at Lumicell. The company is on the precipice of significant innovations and making far-reaching strides in bringing its drug and device therapy to the market where it can help physicians and patients. But what I’m most excited about is Lumicell’s mission. Cancer, infection, wound care—battling these tough diseases is personal. And I look forward to supporting this mission, helping raise the profile of Lumicell’s technology, and improving people’s lives,” Hershberger said in a prepared statement.
Natus Medical (NSDQ:BABY) said last week it appointed Drew Davies as its new chief financial officer and exec VP, effective October 1, replacing interim Sharon Villaverde who will continue as finance VP.
Prior to joining Natus Medical, Davies served as CFO and exec VP of Extreme Networks, and as VP and corporate controller at Marvell Semiconductor before that.
“We are pleased to add a leader of Drew’s caliber to the Natus team. Drew brings a wealth of experience in financial and operational management across the technology industry, where innovation, cost management and constant change are critical to success. I am confident that Drew will complement the strengths of Natus’ executive team and play a key role as we progress forward. On behalf of everyone at Natus, I would also like to thank Sharon for serving as the company’s Interim CFO for the past 2 months. We are grateful that Sharon assumed this role at such an important time, and we look forward to continuing to benefit from her expertise,” prez & CEO Jonathan Kennedy said in a press release.
“I am excited to join Natus during a transformative time in the company’s history. Natus has a demonstrated track record of growth and earnings expansion and I look forward to working with Jonathan and the rest of the management team to drive further success,” Davies said in a prepared release.
- NIH taps Tromberg as Nat’l Institute of Biomedical Imaging and Bioengineering head
- Integra Lifesciences GC & corp VP Gorelick to retire
- BioMedGPS names Tracy as SmartTrak business intelligence CCO
- Myomo taps Frijters as EU biz dev manager
- Pursuit Vascular adds Walpole as NA sales lead
- Allurion Tech expands exec team
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!